All In Biotech

Drug Trial Radar · NCT06597422

A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects

A Phase I, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STSP-0902 Ophthalmic Solution in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

82

Actual

Start

Oct 20, 2024

Primary completion

Jan 23, 2025

Study completion Jan 23, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial is a Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic (PK) characteristics of STSP-0902 ophthalmic solution in healthy subjects following single and multiple administrations. The study plans to enroll 80 healthy subjects and is divided into three stages: the single-dose study stage, the multiple-dose study stage, and the tear PK study stage. The single-dose and multiple-dose study stages are randomized, double-blind, placebo-controlled, dose-escalation designs, while the tear PK study stage is a single-dose, open-label design.

Conditions

  • Neurotrophic Keratitis

Interventions

  • STSP-0902 ophthalmic solutionDrug

    Eye drop, single dose

  • STSP-0902 PlaceboDrug

    Eye drop, single dose

  • STSP-0902 ophthalmic solutionDrug

    Eye drop, three times daily for a total of 8 days

  • STSP-0902 ophthalmic solutionDrug

    Eye drop, six times daily for a total of 8 days

  • STSP-0902 PlaceboDrug

    Eye drop, multiple doses

  • STSP-0902 ophthalmic solutionDrug

    Eye drop, single dose, tear samples will be collected

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events related to study drugTime frame: Baseline to Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.